Haase, Detlef

[["dc.bibliographiccitation.journal","Leukemia Research"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Germing, U."],["dc.contributor.author","Hildebrandt, B."],["dc.contributor.author","Symeonidis, Argiris"],["dc.contributor.author","Cermak, J."],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Noesslinger, T."],["dc.contributor.author","Sekkeres, M."],["dc.contributor.author","Maciejewski, Andrzej J."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Seymour, J."],["dc.contributor.author","Kenealy, M."],["dc.contributor.author","Koeppler, H."],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Blum, S."],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Goetze, K."],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Kreuzer, Karl Anton"],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Kuendgen, A."],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.date.accessioned","2018-11-07T08:30:27Z"],["dc.date.available","2018-11-07T08:30:27Z"],["dc.date.issued","2009"],["dc.format.extent","S74"],["dc.identifier.isi","000266759600107"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16895"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.publisher.place","Oxford"],["dc.relation.conference","10th International Symposium on Myelodysplastic Syndromes"],["dc.relation.eventlocation","Patras, GREECE"],["dc.relation.issn","0145-2126"],["dc.title","Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","191"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","198"],["dc.bibliographiccitation.volume","92"],["dc.contributor.author","Nolte, F."],["dc.contributor.author","Hoechsmann, B."],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Lueck, A."],["dc.contributor.author","Gattermann, Norbert"],["dc.contributor.author","Taupitz, Matthias"],["dc.contributor.author","Baier, M."],["dc.contributor.author","Leismann, O."],["dc.contributor.author","Junkes, A."],["dc.contributor.author","Schumann, Christian"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Schrezenmeier, Hubert"],["dc.date.accessioned","2018-11-07T09:30:38Z"],["dc.date.available","2018-11-07T09:30:38Z"],["dc.date.issued","2013"],["dc.description.abstract","The majority of patients with myelodysplastic syndrome (MDS) present with anemia and will become dependent on regular transfusions of packed red blood cells (PRBC) with the risk of iron overload (IOL). Liver iron content best reflects the total body iron content, and measurement of liver iron concentration (LIC) by MRI is a validated tool for detection, but data in MDS is rather limited. Here we present the results of a multi-center trial evaluating the efficacy and safety of deferasirox (DFX) in low and intermediate-1 risk MDS patients with transfusion-dependent IOL. Three patients with transfusion frequency of > 4 units PRBC per month were initially treated with 30 mg/kg/day while in 46 patients with a lower transfusion burden deferasirox was initiated at 20 mg/kg/day, due to patient related reasons one patient received DFX in a dose of 6 mg/kg/day only. LIC was measured by MRI at baseline and end of study using the method by St. Pierre et al. The intention to treat population consisted of 50 MDS patients (28 male; 22 female) with a median age of 69 years who were treated with DFX for a median duration of 354 days. Mean daily dose of DFX was 19 mg/kg/day. Median serum ferritin level (SF) at baseline was 2,447 ng/mL and decreased to 1,685 ng/mL (reduction by 31 %) at end of study (p = 0.01). In 7 (13 %) patients the initially chosen dose had to be increased due to unsatisfactory efficacy of chelation therapy. For 21 patients, LIC measurement by liver MRI was performed at baseline and for 19 of these patients at the end of study: mean LIC decreased significantly from 16,8 mg/g dry tissue weight (+/- 8.3 mg/g dry tissue weight) at study entry to 10,8 mg/g dry tissue weight (+/- 10.4 mg/g dry tissue weight) at end of study (p = 0.01). Of all patients exposed to the study drug (n = 54), 28 (52 %) did not complete the 12 month study period most commonly due to AEs in 28 % (n = 15) and abnormal laboratory values in 7 % (n = 4), respectively. The most common adverse events (a parts per thousand yenaEuro parts per thousand 10 % of all patients) with suspected drug relationship were diarrhea (n = 25, 46 %), nausea (n = 13, 24 %), upper abdominal pain (n = 8, 15 %), serum creatinine increase (n = 16, 30 %) and rash (n = 5, 9 %). Adverse events making dose adjustments or interruption of study drug necessary occurred in 33 patients (61 %). Hematologic improvement according to IWG criteria (2006) was observed in 6 patients (11 %). Initiation of treatment of IOL with DFX depending on the transfusion burden yields sufficient reduction of excess iron indicated by serum ferritin levels and most importantly by liver MRI. The safety profile of DFX was comparable to previous observations."],["dc.identifier.doi","10.1007/s00277-012-1594-z"],["dc.identifier.isi","000313445100007"],["dc.identifier.pmid","23073603"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31353"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.title","Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Metz, Michael"],["dc.contributor.author","Deitken, Sven"],["dc.contributor.author","Seraphin, Joerg"],["dc.contributor.author","Goetze, Katharina S."],["dc.contributor.author","Mueller-Thomas, Catharina"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Bruemmendorf, Tim Henrik"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Jentsch-Ullrich, Kathleen"],["dc.contributor.author","Boehme, Angelika"],["dc.contributor.author","Bug, Gesine"],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T08:36:46Z"],["dc.date.available","2018-11-07T08:36:46Z"],["dc.date.issued","2010"],["dc.format.extent","1211"],["dc.identifier.isi","000289662203269"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18387"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","52nd Annual Meeting of the American-Society-of-Hematology (ASH)"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","0006-4971"],["dc.title","Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","841"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","850"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Goetze, Katharina S."],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.date.accessioned","2018-11-07T08:39:26Z"],["dc.date.available","2018-11-07T08:39:26Z"],["dc.date.issued","2010"],["dc.description.abstract","Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a substantial risk of progression to acute myeloid leukemia (AML). For many years, the main treatment option for MDS was best supportive care which alleviates symptoms, but has no effect on the natural course of the disease. Recently, demethylating agents have become available as a promising new treatment for patients with MDS. In two randomized clinical trials, the demethylating agent azacitidine has demonstrated a reduced risk of transformation to AML, improvement of peripheral blood values, an improved quality of life, and a definite survival advantage compared to conventional care regimens for patients with International Prognostic Scoring System score of intermediate-2 or high-risk MDS. This review aims to provide practical recommendations for the use of azacitidine and the management of its side effects in patients with MDS, assuring safe administration and best efficacy of treatment."],["dc.description.sponsorship","German Kompetenznetz \"Akute and chronische Leukamien\""],["dc.identifier.doi","10.1007/s00277-010-1015-0"],["dc.identifier.isi","000280226700001"],["dc.identifier.pmid","20567826"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18997"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.title","Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1286"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Leukemia"],["dc.bibliographiccitation.lastpage","1292"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Germing, U."],["dc.contributor.author","Lauseker, Michael"],["dc.contributor.author","Hildebrandt, B."],["dc.contributor.author","Symeonidis, Argiris"],["dc.contributor.author","Cermak, J."],["dc.contributor.author","Fenaux, Pierre"],["dc.contributor.author","Kelaidi, C."],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Noesslinger, T."],["dc.contributor.author","Sekeres, Mikkael A."],["dc.contributor.author","Maciejewski, Andrzej J."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Seymour, J."],["dc.contributor.author","Kenealy, M."],["dc.contributor.author","Weide, Rudolf"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Goetze, K."],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Blum, S."],["dc.contributor.author","Kreuzer, K-A"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Hofmann, W-K"],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Krieger, Otto"],["dc.contributor.author","Kuendgen, A."],["dc.contributor.author","Haas, Rainer"],["dc.contributor.author","Hasford, Joerg"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.date.accessioned","2018-11-07T09:09:41Z"],["dc.date.available","2018-11-07T09:09:41Z"],["dc.date.issued","2012"],["dc.description.abstract","Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease. In order to address the issue of the propensity of those patients to progress to acute myeloid leukemia (AML), data on 381 untreated patients with MDS and del(5q) characterized by low or intermediate I International Prognostic Scoring System (IPSS) risk score were collected from nine centers and registries. Median survival of the entire group was 74 months. Transfusion-dependent patients had a median survival of 44 months vs 97 months for transfusion-independent patients (P<0.0001). Transfusion need at diagnosis was the most important patient characteristic for survival. Of the 381 patients, 48 (12.6%) progressed to AML. The cumulative progression rate calculated using the Kaplan-Meier method was 4.9% at 2 years and 17.6% at 5 years. Factors associated with the risk of AML transformation were high-risk World Health Organization adapted Prognostic Scoring System (WPSS) score, marrow blast count >5% and red-cell transfusion dependency at diagnosis. In conclusion, patients with MDS and del(5q) are facing a considerable risk of AML transformation. More detailed cytogenetic and molecular studies may help to identify the patients at risk of progression."],["dc.description.sponsorship","Celgene"],["dc.identifier.doi","10.1038/leu.2011.391"],["dc.identifier.isi","000305081000016"],["dc.identifier.pmid","22289990"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26315"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","0887-6924"],["dc.title","Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","900"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Leukemia Research"],["dc.bibliographiccitation.lastpage","906"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Götze, Katharina S."],["dc.contributor.author","Müller-Thomas, Catharina"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Brümmendorf, Tim H."],["dc.contributor.author","Bug, Gesine"],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Stadler, Michael"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Blau, Igor W."],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Metz, Michael"],["dc.contributor.author","Detken, Sven"],["dc.contributor.author","Seraphin, Jörg"],["dc.contributor.author","Jentsch-Ullrich, Kathleen"],["dc.contributor.author","Böhme, Angelika"],["dc.contributor.author","Schmidt, Burkhard C."],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:22:10Z"],["dc.date.available","2018-11-07T09:22:10Z"],["dc.date.issued","2013"],["dc.description.abstract","The gold standard of cytogenetic analysis in myelodysplastic syndromes (MDS) is conventional chromosome banding (CCB) analysis of bone marrow (BM) metaphases. Most aberrations can also be detected by fluorescence-in situ-hybridization (FISH). For this prospective multicenter German diagnostic study (www.clinicaltrials.gov: #NCT01355913) 360 patients, as yet, were followed up to 3 years by sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood (PB) cells using comprehensive FISH probe panels, resulting in a total number of 19,516 FISH analyses. We demonstrate that CD34+ PB FISH correlates significantly with CCB analysis and represents a feasible method for a reliable non-invasive cytogenetic monitoring from PB. (C) 2013 Elsevier Ltd. All rights reserved."],["dc.description.sponsorship","Celgene(R) Germany"],["dc.identifier.doi","10.1016/j.leukres.2013.03.019"],["dc.identifier.isi","000321111900012"],["dc.identifier.pmid","23623559"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29278"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","Najko"],["dc.relation.issn","0145-2126"],["dc.title","Molecular cytogenetic monitoring from CD34+peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","124"],["dc.contributor.author","Heuser, Michael"],["dc.contributor.author","Meggendorfer, Manja"],["dc.contributor.author","Cruz, Michelle Maria Araujo"],["dc.contributor.author","Koehler, Larissa"],["dc.contributor.author","Goehring, Gudrun"],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Gutermuth, Annika"],["dc.contributor.author","Panagiota, Victoria"],["dc.contributor.author","Fabisch, Jana"],["dc.contributor.author","Haferlach, Claudia"],["dc.contributor.author","Koenecke, Christian"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Thiede, Christian"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Schroeder, Thomas"],["dc.contributor.author","Kobbe, Guido"],["dc.contributor.author","Ehrlich, Steve"],["dc.contributor.author","Stamer, Kathrin"],["dc.contributor.author","Schlegelberger, Brigitte"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Haferlach, Torsten"],["dc.contributor.author","Thol, Felicitas"],["dc.date.accessioned","2018-11-07T09:31:24Z"],["dc.date.available","2018-11-07T09:31:24Z"],["dc.date.issued","2014"],["dc.identifier.isi","000349233800125"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31530"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","56th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","1528-0020"],["dc.relation.issn","0006-4971"],["dc.title","Casein Kinase 1A1 (CSNK1A1) Is Recurrently Mutated in MDS Patients with Deletion of Chromosome 5q"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Germing, U."],["dc.contributor.author","Schuler, E."],["dc.contributor.author","Schulz, Xenia"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Nolte, F."],["dc.contributor.author","Hofmann, W-K"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Goetze, K."],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Letsch, Anne"],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Bug, G."],["dc.contributor.author","Bruemmendorf, Tim Hendrik"],["dc.contributor.author","Haas, Rainer"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T10:07:38Z"],["dc.date.available","2018-11-07T10:07:38Z"],["dc.date.issued","2016"],["dc.format.extent","235"],["dc.identifier.isi","000385691300581"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39317"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Cytogenetic monitoring from peripheral blood in patients with myelodysplastic syndrome: First results from the German LEMON-5 trial"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Goetze, K."],["dc.contributor.author","Mueller-Thomas, Catharina"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Jung, K."],["dc.contributor.author","Metz, M."],["dc.contributor.author","Detken, Sven"],["dc.contributor.author","Seraphn, J."],["dc.contributor.author","Bruemmendorf, Tim Hendrik"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Germing, U."],["dc.contributor.author","Jentsch-Ullrich, Kathleen"],["dc.contributor.author","Boehme, A."],["dc.contributor.author","Bug, G."],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Stadler, M."],["dc.contributor.author","Hofmann, W.-K"],["dc.contributor.author","Schmidt, B."],["dc.contributor.author","Lubbert, M."],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Blau, Igor W."],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:04:53Z"],["dc.date.available","2018-11-07T09:04:53Z"],["dc.date.issued","2012"],["dc.format.extent","30"],["dc.identifier.isi","000310766700069"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25200"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","0378-584X"],["dc.title","Cytogenetic diagnostics of CD34+peripheral blood cells in MDS: Results from the multicenter German prospective diagnostic CD34+FISH study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Germing, U."],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Kuendgen, A."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Noesslinger, T."],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Goetze, K."],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Blum, S."],["dc.contributor.author","Hildebrandt, B."],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Krieger, Otto"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Hofmann, W-K"],["dc.contributor.author","Braess, J."],["dc.contributor.author","Schulte, K."],["dc.contributor.author","Kreutzer, K-A"],["dc.contributor.author","Buesche, Guntram"],["dc.contributor.author","Kreipe, Hans"],["dc.contributor.author","Stadler, M."],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Meckenstock, G."],["dc.contributor.author","Bug, G."],["dc.contributor.author","Rune, Gabriele M."],["dc.contributor.author","Haas, Rainer"],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Lauseker, Michael"],["dc.contributor.author","Hasford, Joerg"],["dc.contributor.author","Gattermann, Norbert"],["dc.date.accessioned","2018-11-07T08:52:20Z"],["dc.date.available","2018-11-07T08:52:20Z"],["dc.date.issued","2011"],["dc.format.extent","288"],["dc.identifier.isi","000295160600773"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22143"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","0378-584X"],["dc.title","Data from the German-Austrian-Suisse MDS registry (D-A-CH MDS registry)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]